(Cefepime + taniborbactam hydrochloride) is under clinical development by VenatoRx Pharmaceuticals and currently in Phase III for Pyelonephritis. According to GlobalData, Phase III drugs for Pyelonephritis have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Cefepime + taniborbactam hydrochloride)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Cefepime + taniborbactam hydrochloride) overview

Fixed dose combination of cefepime and taniborbactam hydrochloride (VNRX-5133) is under development for the treatment of multi-drug resistant (MDR) gram-negative infections such as carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa infections, complicated urinary tract infections (cUTI) including acute pyelonephritis, pyuria, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. It is administered intravenously. The therapeutic candidate acts by targeting beta lactamase and penicillin binding protein 2.

It was also under development for the treatment of complicated intra-abdominal infections (cIAI).

VenatoRx Pharmaceuticals overview

VenatoRx Pharmaceuticals (VenatoRx) discovers and develops novel anti-infectives for the treatment of multi-drug resistant (MDR) bacterial infections and viral infections. The company’s pipeline portfolio includes taniborbactam, an injectable beta-lactamase inhibitor (BLI), against all the major sub-classes of beta-lactamases; VNRX-7145, an orally bioavailable BLI against both extended spectrum beta-lactamases (ESBLs) and carbapenem-resistant enterobacteriaceae. It is also investigating penicillin binding proteins (PBP) inhibitor program for the treatment of Neisseria gonorrhoeae; and VNRX-9945 for testing HBV infected patients and other novel anti-bacterial and anti-viral programs. The company’s products are indicated in fixed combinations of cephalosporin and cefepime for the treatment of allergy and infectious diseases. VenatoRx is headquartered in Malvern, Pennsylvania, the US.

For a complete picture of (Cefepime + taniborbactam hydrochloride)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.